CLDX
$29.73-0.47 (-1.54%)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Recent News
Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts
Celldex Therapeutics (NASDAQ:CLDX) executives highlighted recent clinical progress and upcoming catalysts during a discussion at the Leerink Partners Global Healthcare Conference, with a major focus on the company’s Phase III program in chronic spontaneous urticaria (CSU) for barzolvolimab. Executi
Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference
Executives from Celldex Therapeutics (NASDAQ:CLDX) outlined a busy year of clinical and development milestones at the TD Cowen Healthcare Conference, highlighting completed enrollments in two Phase 3 chronic spontaneous urticaria (CSU) trials, the launch of a Phase 3 study in chronic inducible urtic
Celldex Therapeutics, Inc. (CLDX): A Bull Case Theory
We came across a bullish thesis on Celldex Therapeutics, Inc. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on CLDX. Celldex Therapeutics, Inc.’s share was trading at $30.82 as of February 25th. Celldex Therapeutics Inc. (CLDX) is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical […]
Is Celldex Therapeutics (CLDX) Pricing Reflecting Recent 46% One-Year Surge And DCF Upside Potential
If you are wondering whether Celldex Therapeutics at around US$30 a share represents fair value or a potential opportunity, this article will walk you through what the current price might be implying. The stock has shown sharp short term moves, with returns of 30.7% over the last 7 days, 21.5% over 30 days, 11.4% year to date and 46.3% over 1 year. These gains are set against a 35.7% decline over 3 years and a 14.8% return over 5 years. These swings are playing out against continuing...
Celldex Therapeutics Stock Earns 88 RS Rating
On Thursday, Celldex Therapeutics stock received an upgrade to its Relative Strength (RS) Rating, from 63 to 88. This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks matches up against that of all other stocks. Is Celldex Therapeutics Stock A Buy?